However, the proportion of younger patients aged 18–44 years was 11.43%, suggesting that gemtuzumab ozogamicin may be used in younger patients with relapsed/refractory AML, high CD33 expression, or specific molecular subtypes. The gene discussed is CD33; the disease is acute myeloid leukemia.